FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2935170882> ?p ?o ?g. }

• W2935170882 abstract "Tranexamic acid (TXA) has been routinely delivered in multisegmental spinal decompression and bone graft fusion surgeries with satisfactory outcomes in minimizing gross blood loss and transfusion demands. However, concerns remain that intravenously delivered TXA (ivTXA) may increase risks of postoperative convulsive seizures and systemic thrombogenicity. Topical use of TXA (tTXA), being more targeted to the surgical bleeding site while minimizing patient systemic exposure to ivTXA, has been successfully applied to attenuate blood losses and transfusion requirements in hip and knee arthroplasty. Yet, randomized controlled trials on tTXA efficacy and safety are still lacking in spinal surgeries. With this knowledge gap, we hypothesize that tTXA exhibits non-inferiority to ivTXA in blood conservation and clinical safety in multisegmental spinal decompression and bone graft fusion surgeries. A prospective, randomized, double-blind, non-inferiority study design will be adopted. The target sample size is 176. Eligible patients will be randomly allocated to receive either ivTXA or tTXA treatment. The primary end point is the perioperative total blood loss. Secondary end points consist of visible blood losses (intraoperative, postoperative 0–24 h, postoperative 0–48 h, combined perioperative blood loss, total postoperative blood loss), postoperative hidden blood loss, plasma TXA levels, postoperative conventional coagulation monitoring (prothrombin time, activated partial thromboplastin time, fiber Bragg grating, international normalized ratio), postoperative thromboelastography monitoring (reaction time, clot formation time, clot strength, fibrinolysis), postoperative hemoglobin nadir (within postoperative 48 h), perioperative transfusion amounts and rates, and length of hospital stay. Safety end points will be monitored too. This proposed study will contribute to expanding clinical evidences of tTXA for bleeding management in major spinal surgeries. This will be a high-quality prospective randomized trial with sufficient sample size, strict methodology, and few design deficits. It will investigate the potentiality of tTXA as an alternative to ivTXA in improving the current standard of care in multisegmental spinal surgeries, thereby optimizing the enhanced recovery after surgery scheme in spinal surgeries. ClinicalTrials.gov, NCT03011866 . Registered on 5 January 2017." @default.
• W2935170882 created "2019-04-11" @default.
• W2935170882 creator A5016249345 @default.
• W2935170882 creator A5027194083 @default.
• W2935170882 creator A5031831495 @default.
• W2935170882 creator A5035575877 @default.
• W2935170882 creator A5040400935 @default.
• W2935170882 creator A5041743736 @default.
• W2935170882 creator A5058625085 @default.
• W2935170882 creator A5082502475 @default.
• W2935170882 creator A5086490669 @default.
• W2935170882 creator A5090283045 @default.
• W2935170882 date "2019-02-12" @default.
• W2935170882 modified "2023-10-18" @default.
• W2935170882 title "Tranexamic Acid in Reducing Gross Hemorrhage and Transfusions of Spine Surgeries (TARGETS): study protocol for a prospective, randomized, double-blind, non-inferiority trial" @default.
• W2935170882 cites W1953205051 @default.
• W2935170882 cites W1964421324 @default.
• W2935170882 cites W1972521229 @default.
• W2935170882 cites W1981196689 @default.
• W2935170882 cites W2018051664 @default.
• W2935170882 cites W2019179832 @default.
• W2935170882 cites W2022045958 @default.
• W2935170882 cites W2032541700 @default.
• W2935170882 cites W2040538032 @default.
• W2935170882 cites W2043912620 @default.
• W2935170882 cites W2063161947 @default.
• W2935170882 cites W2080555918 @default.
• W2935170882 cites W2086064501 @default.
• W2935170882 cites W2088356212 @default.
• W2935170882 cites W2099970124 @default.
• W2935170882 cites W2107224601 @default.
• W2935170882 cites W2128179209 @default.
• W2935170882 cites W2132296965 @default.
• W2935170882 cites W2147517013 @default.
• W2935170882 cites W2147670052 @default.
• W2935170882 cites W2236130351 @default.
• W2935170882 cites W2275919127 @default.
• W2935170882 cites W2299129461 @default.
• W2935170882 cites W2539290297 @default.
• W2935170882 cites W2592330893 @default.
• W2935170882 cites W2605645113 @default.
• W2935170882 cites W2618701102 @default.
• W2935170882 cites W2728243998 @default.
• W2935170882 cites W2765290794 @default.
• W2935170882 cites W2765601169 @default.
• W2935170882 cites W2782274827 @default.
• W2935170882 cites W2791882369 @default.
• W2935170882 cites W4247903468 @default.
• W2935170882 cites W44985736 @default.
• W2935170882 cites W50135966 @default.
• W2935170882 doi "https://doi.org/10.1186/s13063-019-3231-9" @default.
• W2935170882 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6373130" @default.
• W2935170882 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30755256" @default.
• W2935170882 hasPublicationYear "2019" @default.
• W2935170882 type Work @default.
• W2935170882 sameAs 2935170882 @default.
• W2935170882 citedByCount "10" @default.
• W2935170882 countsByYear W29351708822020 @default.
• W2935170882 countsByYear W29351708822021 @default.
• W2935170882 countsByYear W29351708822022 @default.
• W2935170882 crossrefType "journal-article" @default.
• W2935170882 hasAuthorship W2935170882A5016249345 @default.
• W2935170882 hasAuthorship W2935170882A5027194083 @default.
• W2935170882 hasAuthorship W2935170882A5031831495 @default.
• W2935170882 hasAuthorship W2935170882A5035575877 @default.
• W2935170882 hasAuthorship W2935170882A5040400935 @default.
• W2935170882 hasAuthorship W2935170882A5041743736 @default.
• W2935170882 hasAuthorship W2935170882A5058625085 @default.
• W2935170882 hasAuthorship W2935170882A5082502475 @default.
• W2935170882 hasAuthorship W2935170882A5086490669 @default.
• W2935170882 hasAuthorship W2935170882A5090283045 @default.
• W2935170882 hasBestOaLocation W29351708821 @default.
• W2935170882 hasConcept C126322002 @default.
• W2935170882 hasConcept C141071460 @default.
• W2935170882 hasConcept C168563851 @default.
• W2935170882 hasConcept C2776825266 @default.
• W2935170882 hasConcept C2777664302 @default.
• W2935170882 hasConcept C2778261982 @default.
• W2935170882 hasConcept C2778382381 @default.
• W2935170882 hasConcept C2779637338 @default.
• W2935170882 hasConcept C2779792907 @default.
• W2935170882 hasConcept C2780014101 @default.
• W2935170882 hasConcept C2991743468 @default.
• W2935170882 hasConcept C31174226 @default.
• W2935170882 hasConcept C42219234 @default.
• W2935170882 hasConcept C71924100 @default.
• W2935170882 hasConceptScore W2935170882C126322002 @default.
• W2935170882 hasConceptScore W2935170882C141071460 @default.
• W2935170882 hasConceptScore W2935170882C168563851 @default.
• W2935170882 hasConceptScore W2935170882C2776825266 @default.
• W2935170882 hasConceptScore W2935170882C2777664302 @default.
• W2935170882 hasConceptScore W2935170882C2778261982 @default.
• W2935170882 hasConceptScore W2935170882C2778382381 @default.
• W2935170882 hasConceptScore W2935170882C2779637338 @default.
• W2935170882 hasConceptScore W2935170882C2779792907 @default.
• W2935170882 hasConceptScore W2935170882C2780014101 @default.
• W2935170882 hasConceptScore W2935170882C2991743468 @default.
• W2935170882 hasConceptScore W2935170882C31174226 @default.
• W2935170882 hasConceptScore W2935170882C42219234 @default.
• W2935170882 hasConceptScore W2935170882C71924100 @default.

• next